Dr. Choi is the Managing Director of Pytho Partners PanAsia, an entrepreneur's fund for investing in the assets of private and public healthcare companies. He also co-invests as a Venture Partner with several leading international venture capital funds. Before founding Pytho PanAsia, he co-founded Pytho Capital, a research-oriented, life-science specialized hedge fund investing in small-cap,public biotech companies.
Before co-founding Pytho Capital, John was a Principal at the storied venture capital firm of Venrock Associates, the venture investing arm of the Rockefellers. During his tenure there, John focused on Venrock's biotechnology and medical device franchises, working actively with portfolio companies such as Altea Therapeutics, Coley Pharmaceuticals (acquired by Pfizer NYSE:PFE), Sirna Therapeutics (acquired by Merck NYSE: MRK), Celladon Corporation, and Princeton Lightwave. He was also previously involved with investments in Nanogram Devices Corporation (acquired by Wilson Greatbatch NYSE:GB), Targeted Genetics Corporation (NASDAQ:TGEN) and led the investment in Skinetics Biosciences (acquired by Sirna Therapeutics NASDAQ:RNAI).
Prior to Venrock, he worked as an Associate at the San Francisco offices of TVM Capital, an international Venture Capital firm with offices in the US and Europe; But before embarking on his extensive business and investing experience, John was in academia.
He previously served as a Resident in the Departments of Internal Medicine and Genetics at Baylor College of Medicine. He also completed his doctoral thesis at Harvard University conducting nuclear magnetic resonance (NMR) studies of human T-cell surface proteins CD2 and CD4, investigating the structural and functional properties of these proteins in solution.
Currently, John spends much of his time traveling while actively seeking or managing investment opportunities between the United States and Asia.
M.D. Cornell University Medical College, New York Ph.D. Harvard University in Biophysics, Cambridge B.S. Yale College in Applied Math-Physics, New Haven
Sung-wei Chen, MS, CMA
Investment Partner (In Memoriam 9/25/1972 - 9/07/2012: Requiescat in Pace)
Mr. Chen is an Investment Partner of Pytho PanAsia, and the founder and Managing Director of LambdaInnovation, a global technology development and investment company based in Singapore and with operations in the US. LambdaInnovation develops new technology and intellectual property for large corporations and its own portfolio across biotechnology, the physical & material sciences, and information technologies. Having performed strategic analyses of technology, markets, and inventions that have led to investment commitments of over US$100MM+ in the previous 12 months, Mr. Chen leverages his outstanding experience in global company formation as well as an international network of business contacts to benefit Pytho PanAsia's investment portfolio.
Before LambdaInnovation, Sung-wei was a Director of Intellectual Ventures Asia, a global US$5 billion private equity fund investing in technology and intellectual property. He was headquartered in Singapore, but was responsible for technology licensing, invention and business development for the entire Southeast Asia region. While at IV, he was responsible for the formation of IV's offices in Australia, was solely responsible for recruiting inventors in all technology sectors, and negotiated licensing agreements with academic institutions and government entities throughout Asia.
Previous to this, Sung-wei was an investment professional with ARCH Venture Partners, a $1 billion seed and early stage venture capital firm in Seattle, as well as being an experienced technology licensing officer at UCLA. He helped found several technology companies including CantaMetrix (music start-up sold to Sony/Gracenote) and has been an observer on the boards of numerous IT and biotechnology companies.
C.M.A. Certified Management Accountant, IMA global certification M.S. University of Washington in Chemistry, Seattle A.B. UC Berkeley in Chemistry, Berkeley